Compare Sirius XM Holdings Inc (SIRI) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sirius XM Holdings Inc vs Twist Bioscience Corp — how do they compare? Sirius XM Holdings Inc trades at $26.61 (market cap $8.87B), while Twist Bioscience Corp trades at $161.93 (market cap $10.08B). The key difference: Sirius XM Holdings Inc and Twist Bioscience Corp are close in size by market cap, and Sirius XM Holdings Inc pays a 4.1% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sirius XM Holdings Inc for 102 Days and Twist Bioscience Corp for 27 Days on average.
| SIRI | TWST | |
|---|---|---|
Market Cap | $8.87B | $10.08B |
Volume | 4,324,672 | 4,229,037 |
Sector | Media | Health |
52-Week High | $32.59 | $205.00 |
52-Week Low | $19.92 | $25.45 |
Typical Hold Time | 102 Days | 27 Days |
Enterprise Value | $18.16B | $10.01B |
Dividend Yield | 4.1% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sirius XM (SIRI) trades at $26.51, up 2.16% with mixed technical signals showing neutral momentum. The company demonstrates solid fundamentals with a P/E of 10.57 and P/B of 0.75, though recent earnings show volatility with two misses and one beat in the last four quarters. Strong cash flow generation and a new YouTube partnership provide growth catalysts, while high debt levels and competitive pressures remain concerns.
The stock presents a compelling value opportunity with analyst consensus pointing to 30% upside to the $34.43 price target. However, execution risks in advertising expansion and subscription growth, coupled with $10.31 billion in long-term debt, require careful monitoring. Recent institutional buying and positive management commentary suggest confidence in the company's strategic direction.
Twist Bioscience (TWST) trades at $162.43, up 4.36% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical signal with RSI at 29.02 indicating potential oversold conditions. Fundamentally, revenue growth continues (2025: $377M, 2026: $432M projected) but profitability remains elusive with negative margins. Recent partnership with Eli Lilly's TuneLab platform highlights strategic positioning in AI-driven drug discovery.
While analyst consensus favors Buy (73%), the stock trades above the $145.20 target, suggesting limited near-term upside. Key risks include persistent cash burn (-$44M net CF in 2025) and high valuation multiples (P/S: 21.5). The AI biotech partnership provides growth catalyst potential, but profitability timeline remains uncertain for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
